New MOU pairs GlycanAge’s glycan-based biologi

New $1.

A 350-patient study finds a palm-sized ECG devic

Aesthetics empire opens its first wellness clini

Leqembi Iqlik lets patients self-administer anti

Facing a legal challenge to its sleep-tracking c

As longevity clinics multiply and Muse cell bran

Coya Therapeutics has published preclinical resul

Alzheon announced a peer-reviewed publication pre

BioAge Labs announced that it has dosed the first

Elysium opened The Elysium Longevity Institute (T

Function has integrated its health platform with

Allegro reported that its investigational nanotec

Obesity biotech aims to reduce fat while preserv

Obesity biotech aims to reduce fat while preserv

Prevention gets tech budget it deserves as a $49

Prevention gets tech budget it deserves as a $49

Leisure exercise lowers dementia risk, while phy

Leisure exercise lowers dementia risk, while phy

Researchers say disrupted sleep may be one of th

Researchers say disrupted sleep may be one of th

NeuLogiq platform earned high marks from ALS and

Genetic LifeSpan launch MyHeartCode, betting tha

While Spain celebrates football glory, Madrid sc

Moonwalk Biosciences closed an oversubscribed $70

Genflow announced that its SLAB (Sarcopenia and L

Sky Labs presented clinical research on its ring-

AlzeCure Pharma will present at Aktiedagen in Sto

The United Kingdom’s Medicines and Healthcare p

South Korean RNA-editing firm enters Eli Lilly’s San Diego innovation hub to speed its precision gene-therapy pipeline toward the clinic. Biotech real estate has its own hierarchy, and San Diego sits near the top. So when a Seongnam-based RNA therapeutics company buys itself a desk inside Eli Lilly’s newest innovation outpost there, it’s worth asking what that access is actually worth and whether it says more about the company or about Lilly’s appetite for outside science. Rznomics Inc announced that it is joining Lilly Gateway Labs (LGL), the pharma giant’s San Diego hub for biotech companies working alongside its scientists and executives [1]. LGL sits under Lilly Catalyze360, the umbrella that also houses Lilly Ventures, Lilly ExploR&D and Lilly TuneLab – Lilly’s answer to the growing pressure on Big Pharma to source innovation externally rather than build it all in-house. The arrangement gives Rznomics wet-lab space and, perhaps more valuably, proximity. Sitting inside the same building as Lilly scientists tends to accelerate the unglamorous parts of drug development: informal conversations, faster feedback loops, introductions that don’t show up in a press release but decide whether a molecule gets a second look. Rznomics says the move will help it accelerate candidate…

Six proteomic clocks detect a younger biological

PRGS&Tech is South Korea’s only team left in X

NRG Therapeutics unpacks the molecular switch be

The preventive-care clinic adds hormone testing,

Rznomics Inc.

Genflow Biosciences PLC reports that its SLAB (Sa

Insilico Medicine published a study in Nature Bio

Licensing deal brings Amprion’s misfolded-prot

Deal with Singapore’s MuseCell Innovations cou

A newly allowed US patent covers the lipid deliv

Fresh off the world’s largest mammalian longev

A new 10–15 minute series aims to bring clarit

iBio will participate in the Wells Fargo 21st Ann

Longeveron will present at the H.C.

eGenesis provided a clinical update from an ongoi

Alkeus announced the publication in JAMA Ophthalm

Mabwell presented Phase Ib/IIa results for its an

One patient spent nine months off dialysis with

VHH brings its ‘village’ model to Malaysia,

Function Health now lets members feed lab result